Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Martin H. Huber M.D. | President, CEO & Director | 757.95k | -- | 1961 |
| Mr. Brian C. DeSchuytner | Senior VP, CFO & COO | 550.68k | -- | 1978 |
| Dr. Timothy B. Lowinger Ph.D. | Senior VP and Chief Science & Technology Officer | 570.58k | -- | 1964 |
| Ms. Alejandra Veronica Carvajal J.D. | Senior VP, Secretary & Chief Legal Officer | 542.02k | -- | 1974 |
| Mr. Mohan Bala Ph.D. | Senior VP & Chief Development Officer | 533.58k | -- | 1965 |
| Mr. Mikhail Papisov Ph.D. | Co-Founder | -- | -- | -- |
| Mr. Ashish Mandelia | Chief Accounting Officer | -- | -- | 1975 |
| Mr. Jason Fredette | Senior Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Mr. Chuck Miller | Senior Vice President of Regulatory Affairs | -- | -- | -- |
| Dr. Marc Damelin Ph.D. | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop. | -- | -- | -- |
Mersana Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 123
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
February 26, 2025 at 1:30 PM UTC - March 3, 2025 at 1:30 PM UTC
Mersana Therapeutics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available